Patents by Inventor Timothy Charles Kiorpes
Timothy Charles Kiorpes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11904118Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: GrantFiled: December 5, 2019Date of Patent: February 20, 2024Assignee: Micell Medtech Inc.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Publication number: 20230381464Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: ApplicationFiled: August 8, 2023Publication date: November 30, 2023Applicant: MT Acquisition Holdings LLCInventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Patent number: 10729819Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: GrantFiled: October 15, 2018Date of Patent: August 4, 2020Assignee: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Publication number: 20200108232Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: ApplicationFiled: December 5, 2019Publication date: April 9, 2020Applicant: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Publication number: 20190117851Abstract: A drug-eluting product is disclosed comprising an at least partially bioabsorbable element and an active pharmaceutical agent having a morphology, a solubility, and an average particle size which are selected so that the active pharmaceutical agent continues to dissolve during the biodegradation of the bioabsorbable element. The morphology is a crystalline, semi-crystalline or amorphous morphology, the solubility is less than 100 ?g/ml and the average particle size is grater that about 100 nm.Type: ApplicationFiled: December 12, 2018Publication date: April 25, 2019Applicant: Micell Technologies, Inc.Inventors: Timothy Charles Kiorpes, James B. McClain
-
Publication number: 20190046695Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until implantable device is deployed a an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: ApplicationFiled: October 15, 2018Publication date: February 14, 2019Applicant: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Patent number: 10117972Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: GrantFiled: July 12, 2012Date of Patent: November 6, 2018Assignee: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Publication number: 20180085498Abstract: A drug-eluting product is disclosed comprising an at least partially bioabsorbable element and an active pharmaceutical agent having a morphology, a solubility, and an average particle size which are selected so that the active pharmaceutical agent continues to dissolve during the biodegradation of the bioabsorbable element. The morphology is a crystalline, semi-crystalline or amorphous morphology, the solubility is less than 100 ?g/ml and the average particle size is grater that about 100 nm.Type: ApplicationFiled: September 23, 2016Publication date: March 29, 2018Applicant: Micell Technologies, Inc.Inventors: Timothy Charles Kiorpes, James B. McClain
-
Publication number: 20140350522Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: ApplicationFiled: July 12, 2012Publication date: November 27, 2014Applicant: Micell Technologies, Inc.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Publication number: 20130172853Abstract: Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.Type: ApplicationFiled: July 15, 2011Publication date: July 4, 2013Applicant: MICELL TECHNOLOGIES, INC.Inventors: James B. McClain, Charles Douglas Taylor, Brett G. Zani, John Neet, Timothy Charles Kiorpes
-
Publication number: 20120177742Abstract: Devices, coatings, and methods therefore comprise a medical device for delivering nanoparticles of an active agent to a treatment site. A coating on the medical device comprises active agent nanoparticles, which delivers coating to the treatment site and releases active agent nanoparticles into the treatment site over at least one day. A coating may comprise a polymer, a surfactant, and the nanoparticles. The coating may be prepared by forming a nanoemulsion. A coating may comprise encapsulated active agent nanoparticles which comprise active agent nanoparticles encapsulated in a polymer. The coating may have a positive surface charge. The coating may deliver active agent nanoparticles into the treatment site over at least about one day. The coating may be formed of a surfactant and nanoparticles mixture. The active agent nanoparticles may be deposited on the medical device using electrostatic capture.Type: ApplicationFiled: December 29, 2011Publication date: July 12, 2012Applicant: MICELL TECHNOLOGIES, INC.Inventors: James B. McCLAIN, Charles Douglas Taylor, Brett G. Zani, Timothy Charles Kiorpes
-
Patent number: 6800055Abstract: A low attenuation radioactive seed utilizing a core having a fluted or non-circular cross section is utilized for increasing the dose rate, decreasing the dwell times and improving the clinical outcomes by increasing the dose consistency throughout the treatment zone. The fluted or non-circular cross section core would increase the surface area for the deposition of the radioactive substance thereby increasing the therapeutic efficacy of the seed. In addition, the fluted or non-circular cross section may be designed in a manner to reduce photon emission attenuation by reducing the distance an inwardly directed photon would have to travel to traverse the core.Type: GrantFiled: February 21, 2001Date of Patent: October 5, 2004Assignee: Cordis CorporationInventors: Howard Ira Amols, Timothy Charles Kiorpes, Benjamin David McDaniel, Michael Dennis O'Hara
-
Publication number: 20020123660Abstract: A low attenuation radioactive seed utilizing a core having a fluted or non-circular cross section is utilized for increasing the dose rate, decreasing the dwell times and improving the clinical outcomes by increasing the dose consistency throughout the treatment zone. The fluted or non-circular cross section core would increase the surface area for the deposition of the radioactive substance thereby increasing the therapeutic efficacy of the seed. In addition, the fluted or non-circular cross section may be designed in a manner to reduce photon emission attenuation by reducing the distance an inwardly directed photon would have to travel to traverse the core.Type: ApplicationFiled: February 21, 2001Publication date: September 5, 2002Inventors: Howard Ira Amols`, Timothy Charles Kiorpes, Benjamin David McDaniel, Michael Dennis O'Hara